Insider Selling: Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells 75,000 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Mva Investors, Llc sold 75,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $7.43, for a total value of $557,250.00. Following the completion of the sale, the insider now owns 618,524 shares of the company’s stock, valued at $4,595,633.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mva Investors, Llc also recently made the following trade(s):

• On Friday, May 3rd, Mva Investors, Llc sold 60,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.61, for a total value of $456,600.00.

Tango Therapeutics Stock Performance

Tango Therapeutics stock opened at $7.61 on Monday. The stock has a fifty day moving average of $8.58 and a 200-day moving average of $9.34. The stock has a market capitalization of $812.29 million, a P/E ratio of -6.92 and a beta of 0.84. Tango Therapeutics, Inc. has a 52 week low of $2.47 and a 52 week high of $13.03.

Tango Therapeutics (NASDAQ:TNGX) last posted its earnings results on Monday, March 18th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). The company had revenue of $5.43 million during the quarter, compared to the consensus estimate of $7.86 million. Tango Therapeutics had a negative return on equity of 41.96% and a negative net margin of 278.55%. On average, research analysts forecast that Tango Therapeutics, Inc. will post -1.28 earnings per share for the current year.

Hedge Funds Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TNGX. Charles Schwab Investment Management Inc. increased its position in Tango Therapeutics by 205.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 367,357 shares of the company’s stock valued at $4,136,000 after purchasing an additional 247,234 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Tango Therapeutics during the 3rd quarter valued at $653,000. FMR LLC lifted its position in shares of Tango Therapeutics by 12.3% during the 3rd quarter. FMR LLC now owns 11,645,741 shares of the company’s stock valued at $131,131,000 after acquiring an additional 1,276,945 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Tango Therapeutics by 47.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,754,852 shares of the company’s stock valued at $19,760,000 after acquiring an additional 564,971 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Tango Therapeutics by 421.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,793 shares of the company’s stock worth $117,000 after buying an additional 9,530 shares during the last quarter. Institutional investors own 78.99% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on TNGX shares. HC Wainwright raised their price target on shares of Tango Therapeutics from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. Piper Sandler initiated coverage on shares of Tango Therapeutics in a research report on Monday, February 12th. They issued an “overweight” rating and a $18.00 price target for the company. Wedbush reissued an “outperform” rating and set a $18.00 price target on shares of Tango Therapeutics in a research report on Monday, March 18th. Finally, Cantor Fitzgerald initiated coverage on Tango Therapeutics in a research note on Thursday, April 4th. They issued an “overweight” rating for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $17.25.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.